CONFIDENTIAL The information contained in this document is regarded as confidential, and may not be disclosed to another party unless such disclosure is required to initiate the study, to conduct study -related activities, or to comply with national, state, or local laws and regulations . Written authorization from the coordinating site and sponsor is required for disclosure otherwise. PT-PhI-II v05.22.12 RESIST : Patients with IDH1 Positive Recurrent Grade II Glioma Enroll ed in a Safety and Immunogenicity Study of T umor -Specific Peptide Vaccine Document Date: 2017- 10-11 NCT02193347 PT-PhI-II v05.22.12 Duke Cancer Institute Page 1 CONFIDENTIAL RESIST : Patients with IDH1 Positive Recurrent Grade II Glioma Enroll ed in a Safety and Immunogenicity Study of T umor -Specific Peptide Vaccine Sponsor: PI – Duke Cancer Institute Funding Source: NIH Grant Protocol Source: PI - Duke Cancer Institute Duke IRB#: Pro00054746 IND#: 16647 Principal Investigator Katherine Peters, MD, PhD katherine.peters@duke.edu Sub-Investigator(s) Gary Archer, Ph.D. gerald.archer@duke.edu Annick Desjardins, M.D.